FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 350 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Sun Exposure Lowers Risk of Breast Cancer, Study Finds January 6, 2022 EMA Recommends Granting a Marketing Authorisation for Erdafitinib July 10, 2024 Associations Between Genomic Features and Response to Neoadjuvant Treatment in a... August 30, 2022 Anticancer Drugs in the Adjuvant Setting Have Considerable Costs Per Event... July 20, 2022 Load more HOT NEWS Addressing the Barriers to Minority Participation in Cancer Clinical Trials Following Abnormal Cancer Screening Results, Multi-Level Reminders May Increase Follow-Up For Children with Retinoblastoma, Disparities Seen across the Globe Presence of Tumour and Higher Levels of LAG3-positive T-cells in the...
